FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions concerns solid compositions containing agonist GLP-1 and salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid, where the amount of said salt is at least 0.6 or at least 0.8 mmol, and said GLP-1 agonist represents semaglutide, as well as use in medicine for treating type II diabetes or obesity.
EFFECT: group of inventions provides improved action and bioavailability.
28 cl, 1 ex, 10 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| GLP-1 PEPTIDES COMPOSITIONS AND THEIR PRODUCTION | 2013 |
|
RU2641198C2 |
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT AND LUBRICANT | 2019 |
|
RU2807183C2 |
| SOLID COMPOSITIONS CONTAINING GLP-1 AGONIST AND N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID SALT | 2019 |
|
RU2804318C2 |
| ORAL DOSING OF GLUCAGON-LIKE PEPTIDE-1 COMPOUNDS | 2014 |
|
RU2671406C2 |
| SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | 2018 |
|
RU2777206C2 |
| DOUBLE-ACYLATED GLP-1 DERIVATIVES | 2010 |
|
RU2559540C2 |
| DIPEPTIDE, CONTAINING NONPROTEINOGENIC AMINO ACID | 2012 |
|
RU2643515C2 |
| NOVEL GLUCAGON ANALOGUES | 2012 |
|
RU2610175C2 |
| DOUBLE ACYLATED GLP-1 DERIVATIVES | 2012 |
|
RU2602601C2 |
| STABLE PROTRACTED GLP-1/GLUCAGON RECEPTOR CO-ANTAGONISTS FOR MEDICAL USE | 2014 |
|
RU2683039C2 |
